Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
Fig 5
Her2-bridging CAR-CD19 T cells are efficacious in vivo.
A) Dose responsive elimination of pre-established leukemia in an NSG mouse model was monitored after Her2-bridging CAR-CD19 T cells (CAR-142 and CAR-374, donor 36, 99.8% CD3-positive, 67% CD8-positivem, 59% Flag-tag-positive) were administered at doses ranging from 2 x 106 to 1 x 107 cells/mouse. Luminescence values for all cohorts (A) and the treatment cohorts (B) are shown. C-E) CAR T cells (donor 45, 99.2% CD3-positive, 41% CD8-positive, 38% Flag-tag-positive) were evaluated in a SKOV3 ovarian carcinoma model in NSG mice. C) CAR-142 T cells controlled SKOV3 tumor growth while control CAR T cells (CAR-254) had no effect. D) CAR-142 T cell control of SKOV3 tumor growth as compared to CAR-Her2 (CAR-390). CAR-142 and CAR-390 fully controlled tumor growth, while control mice succumbed and had to be euthanized by day 42 (panel E). * = p < 0.001. ** = p < 0.05. NS = no significant differences.